Pfizer
Clinical trials sponsored by Pfizer, explained in plain language.
-
Researchers check how well the new COVID shot works against current variants
⭐️ VACCINE ⭐️ TerminatedThis study looked back at health records to see how well the updated 2024-2025 Pfizer/BioNTech COVID-19 vaccine protected people from getting sick with COVID-19. Researchers analyzed data from CVS MinuteClinic patients aged 5 and older who got tested for the virus and reported sy…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 01, 2026 14:41 UTC
-
Pfizer tests Next-Gen mRNA shot to fight painful shingles
⭐️ VACCINE ⭐️ TerminatedThis study tested a new shingles vaccine made with mRNA technology, similar to some COVID-19 vaccines. It aimed to see if the vaccine was safe and how well it triggered an immune response in healthy adults aged 50 to 85. Researchers compared different versions of the new vaccine …
Phase: PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 04, 2026 15:29 UTC
-
Decade-Long safety watch for groundbreaking duchenne gene therapy
Disease control TerminatedThis study follows boys with Duchenne muscular dystrophy for 10 years after they received an experimental gene therapy in previous Pfizer trials. The goal is to monitor long-term safety and see how well the treatment continues to work over time. Participants will have annual chec…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
First human test of gene therapy for devastating muscle disease
Disease control TerminatedThis early-stage study tested the safety of a single dose of an experimental gene therapy, called PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The main goal was to see if the treatment was safe and tolerable, while also checking if it helped produce the missing mu…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First human test of Pfizer's new cancer drug halted
Disease control TerminatedThis early-stage study aimed to test the safety and find the right dose of a new drug, PF-07265028, for people with advanced cancers that have spread. The drug was tested alone and in combination with another cancer therapy called sasanlimab. The trial was terminated after enroll…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First human test of Pfizer's new cancer fighter
Disease control TerminatedThis early-stage study tested the safety and initial effectiveness of a new drug called PF-07820435, both alone and combined with an existing immunotherapy (sasanlimab), in people with advanced solid tumors. The trial involved a small group of participants with cancers like lung …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First human test for new brain cancer drug halted
Disease control TerminatedThis was a first-in-human study to test the safety and early signs of effectiveness of a new drug, PF-07284890, for people with advanced solid tumors that have a specific genetic change called a BRAF V600 mutation. The trial enrolled 65 participants with cancers like melanoma, lu…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill tested to fight advanced cancers
Disease control TerminatedThis study tested the safety and effects of a new oral drug, PF-06873600, for people with advanced or metastatic breast and ovarian cancers. Participants took the drug alone or combined with standard hormone therapy. The main goals were to find a safe dose and see if the treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Tracking sickle cell patients on new medication for 5 years
Disease control TerminatedThis study followed 265 people with sickle cell disease who were already taking Oxbryta, a medication approved to help manage the condition. Researchers collected real-world data over 5 years to understand how the drug affects patients' blood markers, complications, and quality o…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Smart pen tested to help arthritis patients stick with treatment
Disease control TerminatedThis study looked at whether a smart electronic device for injecting the rheumatoid arthritis drug etanercept helps patients take their medication more consistently. Researchers reviewed the medical records of 60 patients in Colombia over 40 weeks to see if using the device impro…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Early-Stage trial for gut disease pill halted
Disease control TerminatedThis study tested an experimental oral medicine, PF-07054894, to see if it could help control ulcerative colitis. It involved 44 adults with mild to severe forms of the disease who hadn't responded well to standard treatments. The trial was terminated early, and its main goal was…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early-Stage trial tests new drug cocktails for tough lung cancers
Disease control TerminatedThis early-stage study tested whether combining a new immunotherapy drug (sasanlimab) with other targeted cancer therapies was safe and effective for people with advanced non-small cell lung cancer. The trial involved 34 participants and was designed in two parts, testing differe…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First human test of Pfizer's new cancer drug begins
Disease control TerminatedThis early-stage study tested the safety and determined the right dosage of a new drug called PF-08046031 for adults with advanced melanoma and other solid tumors that have spread and have no other approved treatment options. The main goal was to identify side effects and see how…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Lupus skin treatment trial halted after low enrollment
Disease control TerminatedThis study tested an experimental drug called PF-06823859 for adults with lupus who have active skin symptoms. The goal was to see if the drug could reduce skin inflammation and improve symptoms compared to a placebo. The trial was terminated early after enrolling only 8 particip…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Sickle cell patients get extended access to promising drug in safety study
Disease control TerminatedThis study aimed to check the long-term safety of the drug voxelotor for people with sickle cell disease. It was open to patients who had already taken part in earlier voxelotor trials. The main goal was to monitor for side effects and sickle cell complications over a longer peri…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Pfizer tests Long-Term safety of promising sickle cell treatment
Disease control TerminatedThis study aimed to check the long-term safety of the experimental drug GBT021601 for people with sickle cell disease. It enrolled 47 participants who had already taken the drug in earlier trials, allowing them to continue treatment while researchers monitored for side effects ov…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Sickle cell patients get extended access to promising drug in safety Follow-Up
Disease control TerminatedThis study allowed patients with sickle cell disease who had already completed a previous clinical trial of the drug voxelotor to continue taking it long-term. Researchers monitored 179 participants to understand the drug's safety over extended use and whether it continued to hel…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Race for RSV pill: can new drug stop virus from turning deadly?
Disease control TerminatedThis study tested whether an oral medication called sisunatovir could prevent Respiratory Syncytial Virus (RSV) from causing severe illness in high-risk adults. It involved adults with RSV symptoms who were at risk of getting very sick due to age or other health conditions. Half …
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Early-Stage trial halted for aggressive blood cancer treatment
Disease control TerminatedThis early-stage study tested a combination of three medicines for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma that had returned or stopped responding to prior treatment. The trial was for patients who could not receive a stem cell transpla…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
One-Time infusion aims to halt devastating muscle disease in toddlers
Disease control TerminatedThis study tested a one-time gene therapy in boys aged 2 to 4 with Duchenne muscular dystrophy (DMD). The main goals were to check if the treatment was safe and to see if it could help their muscles produce a crucial protein called dystrophin. The trial was small, with 10 partici…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug combo tested for Tough-to-Treat skin cancer
Disease control TerminatedThis study tested two different combinations of cancer drugs for people with advanced melanoma that had a specific genetic change (BRAF mutation) and had stopped responding to a common first-line immunotherapy. Participants received either a three-drug combination (encorafenib, b…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Pfizer halts early trial of new RSV drug for babies
Disease control TerminatedThis study aimed to find a safe and effective dose of an experimental drug called sisunatovir for infants and young children (up to 5 years old) with serious RSV lung infections. It was a small, early-stage trial that compared the drug to a placebo to check for side effects and h…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First patients test new cancer drug in early safety trial
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Real-World look at gut drug for colitis patients
Disease control TerminatedThis study observed how well the approved drug tofacitinib worked for adults in Switzerland with moderate to severe ulcerative colitis. It aimed to gather real-world data on symptom control and gut inflammation by having patients complete questionnaires and use a home stool test.…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Sickle cell patients continue experimental drug to monitor Long-Term safety
Disease control TerminatedThis study aimed to check the long-term safety of inclacumab, an experimental drug for sickle cell disease. It was for people who had already received the drug in a previous Pfizer trial. Participants received the drug every 12 weeks, and researchers tracked any side effects and …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Drug trial aims to protect Kids' brains from sickle cell damage
Disease control TerminatedThis study tested whether a medication called voxelotor could help protect children with sickle cell disease from strokes. It involved about 224 children, aged 2 to 15, who were at risk for stroke due to abnormal blood flow in their brains. Researchers compared the drug to a plac…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
Pfizer tests new drug to fight weight loss in seniors
Symptom relief TerminatedThis study tested a new drug, PF-07258669, to see if it is safe and can help older adults who are losing weight without trying. The goal was to improve appetite and nutrition. It was a small, early-stage trial that was later stopped.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Mar 31, 2026 12:12 UTC
-
Pfizer tests new shot to ease heart failure suffering
Symptom relief TerminatedThis study tested whether a new injectable medicine called Ponsegromab could improve symptoms, physical function, and quality of life for adults with heart failure. About 455 participants received either the study medicine or a placebo injection every four weeks for about nine mo…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Mar 23, 2026 15:16 UTC
-
Pfizer halts Early-Stage drug safety trial
Knowledge-focused TerminatedThis was an early-stage study to check the safety and see how the body processes an experimental oral drug called PF-07899895. It involved 37 healthy adult volunteers who received either the drug or a placebo dummy pill. The main goals were to see if the drug was safe and to meas…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Study collects data on hospital antibiotic use
Knowledge-focused TerminatedThis study aimed to understand how doctors use the antibiotic ceftazidime-avibactam in real-world hospital settings to treat serious infections like pneumonia and abdominal infections. Researchers observed about 220 patients in China who were already prescribed this medication as…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Pfizer halts early test of mystery medicine
Knowledge-focused TerminatedThis was an early-stage study by Pfizer to check the basic safety of a new, unnamed medicine called PF-07314470 and see how the body processes it. It involved a small group of healthy adults who received injections of the medicine or a placebo. The main goal was to identify any s…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC
-
Doctors track new eczema Pill's Real-World impact
Knowledge-focused TerminatedThis study aimed to observe how well the prescription pill abrocitinib works and how safe it is for adults with moderate to severe eczema (atopic dermatitis) in real-world German clinics. It followed 112 patients who were already starting this medication as part of their normal c…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC